CY1111814T1 - Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων - Google Patents

Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων

Info

Publication number
CY1111814T1
CY1111814T1 CY20111100866T CY111100866T CY1111814T1 CY 1111814 T1 CY1111814 T1 CY 1111814T1 CY 20111100866 T CY20111100866 T CY 20111100866T CY 111100866 T CY111100866 T CY 111100866T CY 1111814 T1 CY1111814 T1 CY 1111814T1
Authority
CY
Cyprus
Prior art keywords
carrier protein
patient
diphtheria toxoid
conjugates
meningococcal
Prior art date
Application number
CY20111100866T
Other languages
English (en)
Inventor
Cameron Marshall
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35057184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111814(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0409750A external-priority patent/GB0409750D0/en
Priority claimed from GBGB0500787.7A external-priority patent/GB0500787D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1111814T1 publication Critical patent/CY1111814T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Abstract

Τα συζευγμένα μηνιγγιτιδοκοκκικά καψικά σακχαρίδια θα εισαχθούν μέσα σε χρονοδιαγράμματα ανοσοποίησης στο εγγύς μέλλον, αλλά κατά πρώτον πρέπει να αντιμετωπιστεί το φαινόμενο της «καταστολής φορέα», όπου πρόκειται να χρησιμοποιηθούν πολλαπλά συζεύγματα. Έχει ανευρεθεί ότι το τοξοειδές της διφθερίτιδας και τα παράγωγα αυτού (όπως είναι το CRM 197) μπορεί να χρησιμοποιηθεί με ασφάλεια ως η πρωτεΐνη φορέας, ακόμη και όταν πολλαπλά μηνιγγιτιδοκοκκικά συζεύγματα χορηγούνται κατά τον ίδιο χρόνο και όπου ένας ασθενής έχει εκτεθεί προηγούμενα στην πρωτεΐνη φορέα, είτε με την μορφή ενός προηγούμενου ανοσογόνου (πχ. σε ένα εμβόλιο DTP) ή ως μια προηγούμενη πρωτεΐνη φορέα (πχ. σε ένα εμβόλιο Hib ή ένα εμβόλιο πνευμονοκοκκικών συζευγμάτων). Η εφεύρεση παρέχει μια εφεύρεση για την ανοσοποίηση ενός ασθενούς, περιλαμβάνουσα την χορήγηση πολλαπλών συζευγμάτων μηνιγγιτιδοκκοκικών καψικών σακχαριδίων, όπου το κάθε ένα σύζευγμα περιλαμβάνει μία πρωτεΐνη φορέα του τοξοειδούς της διφθερίτιδας (ή παραγώγου εξ αυτού), και το καψικό σακχαρίδιο, και όπου ο ασθενής έχει προ-ανοσοποιηθεί με ένα τοξοειδές της διφθερίτιδας (ή παράγωγο εξ αυτού).
CY20111100866T 2004-04-30 2011-09-08 Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων CY1111814T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0409750A GB0409750D0 (en) 2004-04-30 2004-04-30 Integration of meningococcal conjugate vaccination
GBGB0500787.7A GB0500787D0 (en) 2005-01-14 2005-01-14 Integration of meningococcal conjugate vaccination
EP05738559A EP1740217B1 (en) 2004-04-30 2005-04-29 Meningococcal conjugate vaccination

Publications (1)

Publication Number Publication Date
CY1111814T1 true CY1111814T1 (el) 2015-10-07

Family

ID=35057184

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100866T CY1111814T1 (el) 2004-04-30 2011-09-08 Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων

Country Status (15)

Country Link
US (2) US9402915B2 (el)
EP (2) EP1740217B1 (el)
JP (2) JP5718545B2 (el)
AT (1) ATE512670T1 (el)
AU (1) AU2005237289B2 (el)
BR (1) BRPI0510315A (el)
CY (1) CY1111814T1 (el)
DK (1) DK1740217T3 (el)
MX (1) MXPA06011994A (el)
NZ (1) NZ550533A (el)
PL (1) PL1740217T3 (el)
PT (1) PT1740217E (el)
RU (1) RU2379052C2 (el)
SI (1) SI1740217T1 (el)
WO (1) WO2005105140A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
EP3009146B1 (en) 2005-06-27 2021-10-20 Pfizer Ireland Pharmaceuticals Immunogenic composition
CA2633772C (en) 2005-12-22 2015-09-15 Ralph Leon Biemans Pneumococcal polysaccharide conjugate vaccine
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CN101265288B (zh) * 2007-03-13 2012-03-21 齐鲁制药有限公司 Crm197突变体的纯化方法
CN101314619B (zh) * 2007-06-01 2010-12-22 齐鲁制药有限公司 肿瘤治疗性疫苗ctp37crm197免疫原及其制备方法与应用
PL2167121T3 (pl) 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
ES2639035T3 (es) 2010-08-23 2017-10-25 Wyeth Llc Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
BR112013030963B1 (pt) 2011-06-01 2020-12-01 Xiamen University proteína de fusão, polinucleotídio, constructo, vetor, célula hospedeira, composição farmacêutica ou vacina, uso da proteína de fusão, método para modificar uma proteína alvo para melhorar sua imunogenicidade e uso do fragmento de crm197 ou um fragmento do mesmo
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013229063B2 (en) 2012-03-09 2016-10-06 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP2906239A1 (en) * 2012-10-12 2015-08-19 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
KR20190044663A (ko) 2016-09-02 2019-04-30 사노피 파스퇴르 인크 네이세리아 메닌기티디스 백신
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB323103A (en) 1928-12-07 1929-12-24 Fred Cunningham Firth Improvements relating to shaper mechanism for winding yarn on weft bobbins in spinning mules
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
PT658118E (pt) 1992-08-31 2002-05-31 Baxter Healthcare Sa Vacinas contra neisseria meningitidis do grupo c
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
JP4233113B2 (ja) 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
EP1082965B1 (en) 1995-06-23 2009-06-10 GlaxoSmithKline Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2201551T3 (es) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP2002502882A (ja) 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２とともに処方された肺炎球菌および髄膜炎菌のワクチン
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP2002520047A (ja) 1998-07-15 2002-07-09 ノボザイムス アクティーゼルスカブ グルコアミラーゼ変異体
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
SI1126876T1 (sl) 1998-10-16 2007-08-31 Glaxosmithkline Biolog Sa Adjuvantni sistemi in vakcine
HUP0200664A2 (en) 1999-03-19 2002-06-29 Smithkline Beecham Biolog Streptococcus vaccine
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
MXPA02006962A (es) * 2000-01-17 2002-12-13 Chiron Spa Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b.
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
EA011480B1 (ru) 2000-06-29 2009-04-28 Глаксосмитклайн Байолоджикалс С.А. Поливалентная вакцинная композиция
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
AP1897A (en) * 2001-01-23 2008-10-10 Aventis Pasteur Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
PT1490409E (pt) 2002-03-26 2009-04-03 Novartis Vaccines & Diagnostic Sacáridos modificados possuindo uma estabilidade melhorada em água
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
EP1506007B1 (en) 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
AU2003257003A1 (en) 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
GB0217909D0 (en) 2002-08-01 2002-09-11 Du Pont Chintzed stretch fabrics
SI2351579T1 (sl) 2002-10-11 2017-05-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
US10272147B2 (en) 2003-01-30 2019-04-30 Glaxosmithkline Biologicals S.A. Injectable vaccines against multiple meningococcal serogroups
EP1626737A2 (en) * 2003-05-07 2006-02-22 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
EP2386313A1 (en) 2003-05-07 2011-11-16 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
EP2364725A3 (en) 2003-06-23 2012-05-09 Sanofi Pasteur Inc. Immunization method against neisseria meningitidis serogroups a and c
AU2004281630A1 (en) * 2003-08-06 2005-04-28 Bio-Manguinhos/Fiocruz Process for preparing polysaccharide-protein conjugate vaccines
NZ550533A (en) * 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
AU2006327023A1 (en) 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines

Also Published As

Publication number Publication date
MXPA06011994A (es) 2007-01-25
ATE512670T1 (de) 2011-07-15
JP5718545B2 (ja) 2015-05-13
EP1740217A2 (en) 2007-01-10
EP2272531A2 (en) 2011-01-12
US20090060945A1 (en) 2009-03-05
WO2005105140A2 (en) 2005-11-10
SI1740217T1 (sl) 2011-10-28
US9402915B2 (en) 2016-08-02
DK1740217T3 (da) 2011-09-26
RU2006142158A (ru) 2008-06-20
AU2005237289B2 (en) 2011-08-04
JP2013116915A (ja) 2013-06-13
EP1740217B1 (en) 2011-06-15
AU2005237289A1 (en) 2005-11-10
US20160303215A1 (en) 2016-10-20
EP2272531A3 (en) 2011-04-13
US10064932B2 (en) 2018-09-04
WO2005105140A3 (en) 2006-01-19
NZ550533A (en) 2010-02-26
PT1740217E (pt) 2011-08-02
PL1740217T3 (pl) 2012-03-30
BRPI0510315A (pt) 2007-10-16
JP2007535527A (ja) 2007-12-06
RU2379052C2 (ru) 2010-01-20

Similar Documents

Publication Publication Date Title
CY1111814T1 (el) Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων
CY1110140T1 (el) Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
MA25824A1 (fr) Compostion de vaccin polyvalente
TW200738258A (en) Vaccine
NO20015073L (no) Vaksiner
CY1114041T1 (el) Ενεσιμα εμβολια εναντι πολλαπλων οροομαδων μηνιγγιτιδοκοκκου
SG151253A1 (en) Combination vaccines with low dose of hib conjugate
DK2004225T3 (da) Programmer for vaccination med meningocockonjugater
MX340096B (es) Formulaciones de vacuna meningococica.
CR10123A (es) Vacuna.